Association between vancomycin minimum inhibitory concentration and mortality among patients with staphylococcus aureus bloodstream infections: A systematic review and meta-analysis

JAMA - Journal of the American Medical Association

Volumn 312, Issue 15, 2014, Pages 1552-1564

  Kalil, Andre C ^a   Van Schooneveld, Trevor C ^a   Fey, Paul D ^b   Rupp, Mark E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BLOODSTREAM INFECTION; CAUSE OF DEATH; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; HUMAN; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; RISK ASSESSMENT; STAPHYLOCOCCAL BACTEREMIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANTIBIOTIC RESISTANCE; BACTEREMIA; MICROBIAL SENSITIVITY TEST; REVIEW; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84908146651     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.6364     Document Type: Article

References (66)

1. Boyce JM, Cookson B, Christiansen K, et al. Methicillin-resistant Staphylococcus aureus. Lancet Infect Dis. 2005;5(10):653-663.
2. Ziakas PD, Anagnostou T, Mylonakis E. The prevalence and significance of methicillin-resistant Staphylococcus aureus colonization at admission in the general ICU setting. Crit Care Med. 2013;42(2): 433-444.
3. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in europe 2012. annual report of the European Antimicrobial Resistance Surveillance Network (Ears-Net). http://ecdc.europa.eu/en/publications /Publications/antimicrobial-resistance-surveillance -europe-2012.pdf. Accessed November 30, 2013.
4. Barnett AG, Page K, Campbell M, et al The increased risks of death and extra lengths of hospital and ICU stay from hospital-acquired bloodstream infections. BMJ Open. 2013;3(10): e003587.
5. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycinsusceptible clinical methicillin-resistant S aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60(4):788-794.
6. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections. Clin Infect Dis. 2012;54(6):755-771.
7. Mavros MN, Tansarli GS, Vardakas KZ, Rafailidis PI, Karageorgopoulos DE, Falagas ME. Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections. Int J Antimicrob Agents. 2012;40(6): 496-509.
8. Jacob JT, DiazGranados CA. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections. Int J Infect Dis. 2013;17(2):e93-e100.
9. Wells G, Shea B, O'Connell D; et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical -epidemiology/oxford.asp. Accessed June 6, 2014.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
11. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Identifying and quantifying heterogeneity. In: Introduction toMeta-analysis. Chichester, United Kingdom: John Wiley & Sons; 2009.
12. Borenstein M, Hedges LV, Higgins JP, Rothstein H.Meta-regression. In: Introduction to Meta-analysis. Chichester, United Kingdom: John Wiley & Sons; 2009.
13. Stroup DF, Berlin JA, Morton SC, et al; Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.Meta-analysis of observational studies in epidemiology. JAMA. 2000;283(15):2008-2012.
14. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses. BMJ. 2009; 339:b2535.
15. Mulrow CD, Cook D. Systematic Reviews: Synthesis of Best Evidence for Health Care Decisions. Philadelphia, Pennsylvania: American College of Physicians; 1998.
16. Sterne JA, Gavaghan D, Egger M. Publication and related bias inmeta-analysis. J Clin Epidemiol. 2000;53(11):1119-1129.
17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.
18. Schwaber MJ,Wright SB, Carmeli Y, et al. Clinical implications of varying degrees of vancomycin susceptibility inmethicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis. 2003;9(6):657-664.
19. Charles PG,Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38(3):448-451.
20. Howden BP,Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38(4):521-528.
21. Maor Y, Rahav G, Belausov N, Ben-David D, Smollan G, Keller N. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol. 2007;45(5):1511-1514.
22. Neoh HM, Hori S, Komatsu M, et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob. 2007;6:13.
23. Liao CH, Chen SY, Huang YT, Hsueh PR. Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an emergency department of a medical centre in Taiwan. Int J Antimicrob Agents. 2008;32(4):326-332.
24. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52(9):3315-3320.
25. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193-200.
26. Bae IG, Federspiel JJ,Miró JM, et al; International Collaboration on Endocarditis-Microbiology Investigator. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis. J Infect Dis. 2009;200(9):1355-1366.
27. Fong RK, Low J, Koh TH, Kurup A. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycinintermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis. 2009;28(8):983-987.
28. Jang HC, Kim SH, Kim KH, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2009;49(3):395-401.
29. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S aureus bacteremia. J Infect Dis. 2009;199(5):619-624.
30. Musta AC, Riederer K, Shemes S, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2009;47(6): 1640-1644.
31. Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and theminimum inhibitory concentration of vancomycin. Clin Infect Dis. 2009;48(7):997-998.
32. Lalueza A, Chaves F, San Juan R, Daskalaki M, Otero JR, Aguado JM. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? J Infect Dis. 2010;201(2):311-312.
33. Lewis T, Chaudhry R, Nightingale P, Lambert P, Das I.Methicillin-resistant Staphylococcus aureus bacteremia. Int J Infect Dis. 2011;15(2):e131-e135.
34. Lin SH, Liao WH, Lai CC, et al. Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan. J Antimicrob Chemother. 2010;65(8):1792-1798.
35. Moore CL, Osaki-Kiyan P, Perri M, et al. USA600 (ST45) methicillin-resistant Staphylococcus aureus bloodstream infections in urban Detroit. J Clin Microbiol. 2010;48(6):2307-2310.
36. Neuner EA, Casabar E, Reichley R, McKinnon PS. Clinical,microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2010;67(3):228-233.
37. Takesue Y, Nakajima K, Takahashi Y, et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother. 2011;17(1):52-57.
38. Wang JL,Wang JT, Sheng WH, Chen YC, Chang SC. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan. BMC Infect Dis. 2010;7(10):159.
39. Aguado JM, San-Juan R, Lalueza A, et al. High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia. Emerg Infect Dis. 2011;17(6):1099-1102.
40. Clemens EC, Chan JD, Lynch JB, Dellit TH. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes inmethicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2011; 71(4):408-414.
41. de Sanctis JT, Swami A, Sawarynski K, et al. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia? Diagn Mol Pathol. 2011;20(3): 184-188.
42. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011;204(3):340-347.
43. Honda H, Doern CD, Michael-Dunne W,Jr, Warren DK. The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia. BMC Infect Dis. 2011;5(11):335.
44. Khatib R, Jose J, Musta A, et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2011;66(7):1594-1599.
45. Schweizer ML, Furuno JP, Sakoulas G, et al. Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients. Antimicrob Agents Chemother. 2011;55(3):1082-1087.
46. van Hal SJ, Jones M, Gosbell IB, Paterson DL. Vancomycin heteroresistance is associated with reduced mortality in ST239methicillin-resistant Staphylococcus aureus blood stream infections. PLoS One. 2011;6(6):e21217.
47. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2011; 66(10):2386-2392.
48. Chen SY, Liao CH,Wang JL, et al. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration. Clin Infect Dis. 2012;55(10):1329-1337.
49. Han JH, Mascitti KB, Edelstein PH, Bilker WB, Lautenbach E. Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2012;56(10):5164-5170.
50. Miller CE, Batra R, Cooper BS, et al. An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection. Clin Infect Dis. 2012;54(5): 591-600.
51. Rojas L, Bunsow E, Munoz P, Cercenado E, Rodriguez-Creixems M, Bouza E. Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients. J Antimicrob Chemother. 2012;67(7):1760-1768.
52. Yeh YC, Yeh KM, Lin TY, et al. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia. JMicrobiol Immunol Infect. 2012;45(3): 214-220.
53. Gasch O, Camoez M, Dominguez MA, et al; REIPI/GEIH Study Groups. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection. Clin Microbiol Infect. 2013;19(11):1049-1057.
54. Kan LP, Lin JC, Chiu SK, et al. Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients. JMicrobiol Immunol Infect. 2014;47(1):15-22.
55. Yoon YK, Park DW, Sohn JW, et al. Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-associated methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2014;58 (1):317-324.
56. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clin Infect Dis. 2011;52(8):969-974.
57. Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin dosing in critically ill patients. Antimicrob Agents Chemother. 2011; 55(6):2704-2709.
58. Clinical and Laboratory Standards Institute. M100-S23 performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. http://clsi.org/wp-content/uploads /sites/14/2013/07/FDA-CrossWalk-Web1.pdf. Accessed April 1, 2014.
59. Edwards B, Milne K, Lawes T, Cook I, Robb A, Gould IM. Is vancomycin MIC "creep"method dependent? J Clin Microbiol. 2012;50(2):318-325.
60. Pitz AM, Yu F, Hermsen ED, Rupp ME, Fey PD, Olsen KM. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S aureus isolates. J Clin Microbiol. 2011;49(1):269-274.
61. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012;25(2):362-386.
62. van Hal SJ, Patterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55(1):405-410.
63. Cameron DR,Ward DV, Kostoulias X, et al. Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. J Infect Dis. 2012;205 (11):1677-1687.
64. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):285-292.
65. Ludwig F, Edwards B, Lawes T, Gould IM. Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2012;50(10):3383-3387.
66. Fowler VG,Jr, Boucher HW, Corey GR, et al Daptomycin vs standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653-665.